Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 2Phase 1 2Phase NA 1Phase EARLY_PHASE1 1Phase 3 1

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Sturge-Weber Syndrome 1Premature Birth 1Hemangioma, Capillary 1

Interventions

Cyclophosphamide 416Radiotherapy 276fludarabine 238Gemcitabine 211Cisplatin 203Nivolumab 184pembrolizumab 183Paclitaxel 176Carboplatin 168Magnetic Resonance Spectroscopy 166fludarabine phosphate 156Irinotecan 135Bevacizumab 133Cytarabine 128Specimen Handling 124Capecitabine 124Temozolomide 123Radiosurgery 118Docetaxel 116Biopsy 116Ipilimumab 113Dexamethasone 113Radiation 111Oxaliplatin 110Fluorouracil 110Rituximab 108Etoposide 108Filgrastim 99Lenalidomide 98Everolimus 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × OTHER × Timolol × Clear all
NCT01533376 2019-03-21

Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol

Wills Eye

Phase 1 Terminated
3 enrolled

Sturge-Weber Syndrome

NCT01434849 2016-11-15

TiPPIH

The University of Texas Health Science Center at San Antonio

Phase 1 Terminated
26 enrolled

Hemangioma, Capillary, Premature Birth

Data powered by HemOnc (CC BY 4.0) Colophon âš¡